Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
ORIC Pharmaceuticals, Inc. reported a net loss of $35.8M for the quarter ended March 31, 2026, compared with $30.0M a year earlier, as it increased investment in its lead oncology programs.
Research and development expenses rose to $31.4M from $24.6M, driven mainly by higher external costs for prostate cancer candidate rinzimetostat and lung cancer candidate enozertinib, while general and administrative expenses were stable at about $8.2M.
ORIC strengthened its balance sheet with $59.9M of net proceeds from at-the-market stock sales, helping lift total cash, cash equivalents and investments to $419.7M. Management believes this liquidity will fund the current operating plan into the second half of 2028 as the company prepares a Phase 3 trial for rinzimetostat and advances multiple Phase 1b studies for enozertinib.
ORIC Pharmaceuticals reported a first quarter 2026 net loss of $35.8 million, or $0.34 per share, as it advanced two oncology programs. The company selected a 400 mg once-daily dose of rinzimetostat with darolutamide for the Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC, expected to start in 1H 2026, supported by favorable safety and landmark rPFS data.
ORIC also reported early rinzimetostat data in post-AR inhibitor mCRPC and continued Phase 1b development of enozertinib across multiple NSCLC settings, with several data updates anticipated in 2H 2026. Cash, cash equivalents and investments were $419.7 million as of March 31, 2026, including $59.9 million raised via an ATM program, which ORIC expects will fund operations into 2H 2028.
ORIC Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 18, 2026. Holders of 103,517,562 shares of common stock as of April 20, 2026 can vote online. The ballot includes electing two Class III directors (Jacob M. Chacko and Mardi C. Dier), ratifying KPMG LLP as auditor for 2026, approving an amended 2020 Equity Incentive Plan that reduces the annual evergreen increase to 4%, caps incentive stock options at 10,000,000 shares and removes the board’s unilateral ability to run option exchange programs, plus advisory votes on executive pay and the frequency of future say‑on‑pay votes. The board describes its largely independent, staggered board structure and details higher 2026 cash retainers and larger option grants for non‑employee directors.
ORIC Pharmaceuticals reported updated Phase 1b dose optimization data for rinzimetostat (ORIC-944), its PRC2 inhibitor, in metastatic castration-resistant prostate cancer, and is advancing a 400 mg once-daily dose into Phase 3 in combination with darolutamide.
The 400 mg regimen showed strong prostate-specific antigen (PSA) responses in post-abiraterone patients, with 47% achieving PSA50 and 33% achieving confirmed PSA50, alongside broad and deep PSA declines. Safety data across post-abiraterone and broader post-ARPI populations showed most treatment-related adverse events were Grade 1–2, no Grade 5 events, and only 6–11% Grade 3 events at 400 mg, supporting long-term dosing and adherence.
Exposure–response analyses across 113 patients found no correlation between higher exposure and better efficacy, but higher exposure was associated with more toxicity and dose modifications, reinforcing 400 mg as the recommended Phase 3 dose. Early landmark radiographic progression-free survival rates compared favorably to competitor regimens while using a lower-intensity schedule. The company also highlighted a second late-stage candidate, enozertinib (ORIC-114), and reported cash and investments of about $392 million as of December 31, 2025, plus roughly $20 million raised afterward, providing runway into the second half of 2028.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported option exercises and share sales in Oric Pharmaceuticals, Inc. common stock. On February 24, 2026, he exercised stock options for 52,000 shares at an exercise price of $4.36 per share, increasing his common stock holdings before any sale.
On the same date, he then sold 52,000 shares of common stock in open-market transactions at a weighted average price of $13.5132 per share, within a range of $13.50 to $13.53, under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2025. Following these transactions, he directly owned 68,148 shares of Oric Pharmaceuticals common stock.
ORIC Pharmaceuticals, Inc. is offering up to $200.0 million of common shares through a renewed at-the-market program under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement under its automatic shelf registration.
The company previously sold 13,478,432 shares for approximately $139.7 million in gross proceeds under a 2024 prospectus supplement, and no further sales will occur under that earlier supplement. A legal opinion from Wilson Sonsini Goodrich & Rosati related to the new offering is filed as an exhibit.
ORIC Pharmaceuticals filed a prospectus supplement to increase its at-the-market sales program with Jefferies to permit up to $200.0 million of common stock to be sold from time to time under the sales agreement.
The supplement states $139.7 million of gross proceeds were raised from 13,478,432 shares previously sold under the agreement, and that 98,528,949 shares were outstanding as of December 31, 2025. Jefferies may sell shares as agent at its discretion and will receive commissions up to 3.0% of gross proceeds.
ORIC Pharmaceuticals, a clinical-stage oncology company, filed its annual report outlining progress on two lead drug candidates and its 2025 financials. The company is advancing rinzimetostat for metastatic castration-resistant prostate cancer toward a first global Phase 3 trial planned for the first half of 2026, and enozertinib for EGFR-mutated lung cancer toward potential Phase 3 monotherapy development.
In 2025, ORIC recorded research and development expenses of $109.8 million and general and administrative expenses of $33.2 million, leading to a net loss of $129.5 million. Cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025, after raising substantial capital through a $125 million May 2025 private placement and approximately $117.6 million of at-the-market share sales.
The company expects its current cash resources to fund its operating plan into the second half of 2028, even after a strategic pipeline refocus and roughly 20% workforce reduction to concentrate on its two lead clinical programs.